AC2993 (synthetic exendin-4)

In preclinical studies to date:

• Reduced food intake

• Biologically active via non-injectable routes

• Conversion of non-insulin producing cells into insulin producing cells

In clinical studies to date:

• Stimulated insulin secretion

• Reduced post-meal glucagon

• Reduced blood glucose levels
  • Post-meal and overnight

CLINICALSTUDIES

Previous slide

Next slide

Back to first slide

View graphic version